Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90)Cong-Truong Nguyen, Jihyae Ann, Raghaba Sahu, et al.
International Journal of Cancer|July 2, 2021
Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancerChihwan Cha, Sung Gwe Ahn, Dooreh Kim, et al.
Molecular Cancer|November 21, 2020
A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancerJung Min Park, Yoon-Jae Kim, Soeun Park, et al.
Cell Death Discovery|November 14, 2021
The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cellsSoeun Park, Yoon-Jae Kim, Jung Min Park, et al.
Scientific Reports|August 6, 2020
Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapySoong June Bae, Yoon Jin Cha, Changik Yoon, et al.
Experimental Hematology & Oncology|October 23, 2025
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancerDongmi Ko, Soeun Park, Minsu Park, et al.
Cellular and Molecular Life Sciences : CMLS|May 15, 2023
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinaseJuyeon Seo, Minsu Park, Dongmi Ko, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 4, 2023
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFRSeongjae Kim, Jung Min Park, Soeun Park, et al.
International Journal of Molecular Medicine|February 6, 2026
Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancerEunsun Jung, Ji Young Kim, Dongmi Ko, et al.
Oncology Reports|November 14, 2025
C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBCEunsun Jung, Yoon-Jae Kim, Kyoungmin Lee, et al.
Pageof 6